Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 3/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.41 |
| ▸ | JAK1 | P23458 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 3/20 | 0.39 |
| ▸ | TYK2 | P29597 | 2/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19896193 | 1.00 | JAK3 (0.45) | JAK3GPR119JAK1POLBJAK2 | |
| SCHEMBL19896198 | 1.00 | JAK3 (0.45) | JAK3GPR119JAK1POLBJAK2 | |
| SCHEMBL1299764 | 0.86 | KDM4E (0.44) | JAK3GPR119JAK1POLBJAK2 | |
| SCHEMBL34474277 | 0.80 | HPGDS (0.53) | JAK3GPR119JAK1JAK2TYK2 | |
| SCHEMBL948255 | 0.79 | GPR119 (0.53) | JAK3GPR119JAK1POLBJAK2 | |
| SCHEMBL9965876 | 0.79 | JAK3 (0.41) | JAK3GPR119JAK1POLBJAK2 | |
| SCHEMBL12836454 | 0.79 | JAK3 (0.41) | JAK3GPR119JAK1POLBJAK2 | |
| SCHEMBL15551483 | 0.79 | HPGDS (0.54) | JAK3GPR119JAK1JAK2TYK2 | |
| SCHEMBL27165344 | 0.76 | OXTR (0.43) | JAK3GPR119JAK1POLBJAK2 | |
| SCHEMBL28766702 | 0.75 | NR1H2 (0.44) | JAK3GPR119JAK1NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180057507-A1 | INHIBITORS OF DUAL LEUCINE ZIPPER (DLK) KINASE FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2018-03-01 | — | — | US | disclosed |
| US-20180057507-A1 | INHIBITORS OF DUAL LEUCINE ZIPPER (DLK) KINASE FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180057507-A1 | INHIBITORS OF DUAL LEUCINE ZIPPER (DLK) KINASE FOR THE TREATMENT OF DISEASE | CLK1, MAP3K12, CLK4 | JAK3 683/4885GPR119 997/4885JAK1 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.